Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Use of Plaque Modifying Devices in Calcified Left Main Lesions

Treating severely calcified left main coronary artery (LMCA) lesions is one of the greatest challenges in interventional cardiology. Adequate pre-stenting lesion preparation is paramount for clinical outcome optimization and stent underexpansion reduction, associated to adverse events such as in stent thrombosis or restenosis. 

Utilización de dispositivos modificadores de placa en lesiones calcificadas del tronco

In this context, plaque modifying devices (PMDs) such as rotational atherectomy (RA), intravascular lithotripsy (IVL) and excimer laser coronary atherectomy (ELCA), have been developed, and become essential to treat these complex lesions. 

Farag et al. have recently published in the Journal of Interventional Cardiology a retrospective analysis looking at clinical outcomes from 302 patients with severely calcified left main stenosis treated with one of these three plaque modifying devices, at a high volume UK center. Most cases were treated with RA (79%), while the use of IVL and ELCA was lower (10% and 11%, respectively).

85.8% of RA and IVL procedures were done on unprotected left main arteries, with high clinical and anatomical complexity (mostly using provisional stenting). Over half of patients (55%) were admitted with acute coronary syndrome (ACS). Despite these high risk profile, technical success rate resulted remarkably high (98.7%), with a procedural success rate of 95.4%. 

Read also: Balloon-Expandable Myval Valve Four-Year Outcomes.

The analysis of hard end points such as long term mortality (42-month mean followup), reported a 19.9% global mortality rate, with no statistically significant differences between the groups (RA: 23.4%; IVL: 3.3%; ELCA: 15.6%; p=0.128). This suggests device type might not be the main determining prognostic factor at long term. 

Multivariable analysis identified chronic kidney failure, a history of cardiac failure, low hemoglobin levels, elevated non -HDL cholesterol and using the transfemoral approach as independent mortality predictors. 

Read also: Conduction Disorders Before TAVR: What Is Their Impact?

As regards safety outcomes, procedural complications were significantly more frequent among ELCA patients (21.9% vs. 2.5% with RA; p=0.018), which was attributed to greater baseline complexity of cases treated with this technique (habitually as a bailout strategy, when unable to use RA or IVL). We should note that this higher complications rate did not translate into worse clinical evolution during hospitalization.

Conclusions

This study by Farag et al. supports the safety and efficacy of plaque modifying devices in the treatment of severely calcified left main lesions. Intravascular imaging guidance, with individualized device selection according to anatomy and operator experience led to high technical success, low in-hospital events incidence and over 80% overall survival. 

Original Title: Clinical Outcomes Following Atherectomy of Calcified Left Main Coronary.

Reference: Farag, Mohamed, Gungoren, Fatih, Al-Atta, Ayman, Abdalazeem, Ibrahem, Bawamia, Bilal, Alkhalil, Mohammad, Egred, Mohaned, Clinical Outcomes Following Atherectomy of Calcified Left Main Coronary, Journal of Interventional Cardiology, 2025, 9605550, 9 pages, 2025. https://doi.org/10.1155/joic/9605550.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...